Search results for " erythropoietin"
showing 10 items of 39 documents
Erythropoietin and its lost receptor
2007
When Neuroprotection Becomes a Potential Ally of High-Grade Glioma.
2019
Despite the use of multimodal treatment regimens, high-grade gliomas (HHGs) are tumors invariably associated with a poor prognosis. The median patient survival after diagnosis is approximately 1 year, through surgery/radiation and chemotherapy treatments.To date, traditional approaches fail to treat efficiently HHGs because surgery does not completely remove the tumor without damaging the brain, radiation therapy cannot be used beyond a certain threshold dose, and chemotherapy has shown limited efficacy and toxic effects. Notwithstanding many attempts at improving outcome using novel agents, the treatment of this disease has not improved in more than a decade. Although scientific and techno…
Mast cells in canine mammary gland tumour: number, distribution and EPOR positivity.
2011
Erythropoietin (EPO)-mediated mitogenic and anti-apoptotic effects involve all the cells expressing functional receptors for EPO (EPOR), as demonstrated by in vitro and in vivo studies. EPO shows pleiotropic effects and acts as an endogenous mediator of adaptive tissue response to metabolic stress protecting tissues from different injuries. Recently, the EPO/EPOR complex has been identified in several neoplastic cell lines and solid tumours. In this study, the authors investigated the mast cells (MCs) number, distribution and their immunoreactivity for EPOR in normal, dysplastic and neoplastic canine mammary gland. The results showed that MCs were more numerous in displastic glands compared…
The many faces of erythropoietin: from erythropoiesis to a rational neuroprotective strategy
2008
It has been more than 10 years since the discovery that erythropoietin (EPO) and its receptor are expressed by the nervous system. In that brief time, a remarkable acceleration in understanding the...
Reticulocytes in untreated obstructive sleep apnoea.
2008
Background and Aim. The short, repetitive hypoxaemic episodes observed in obstructive sleep apnoea (OSA) may determine small augmentations in mature red blood cells. It is unknown whether they affect reticulocyte release. This study explored whether the number and degree of maturation of circulating reticulocytes may be altered in OSA, possibly through the effect of erythropoietin. Methods. Fifty male adult patients with suspected OSA, normoxic during wakefulness, were studied. After nocturnal polysomnography, a blood sample was withdrawn for blood cells count, erythropoietin, iron and transferrin determination. Reticulocyte concentration and degree of immaturity [high (H), medium (M), or l…
Neuroprotective role of erythropoietin in spinal cord ischemic injury: Where have we been and where are we going?
2018
I read with great interest the study recently published by Yamanaka and colleagues,1 reporting the results of the study aimed to pharmacologically induce b common receptor (bcR) subunit upregulation before ischemia to optimize the neuroprotective effect of erythropoietin (EPO). The authors hypothesized that bcR subunit upregulation by diazoxide (DZ) before ischemia amplifies the neuroprotective effects of EPO in mice after spinal cord injury (SCI). They reported that that optimal bcR upregulation occurred at 36 hours after DZ administration, and the optimal DZ dosage for bcR induction was 20 mg/kg. Motor function at 48 hours after treatment was significantly better preserved in the DZ with …
Down with the erythropoietin. Long live the erythropoietin!
2009
In recent years the use of erythropoietin has exploded, and the anaemia of patients with chronic renal failure has been practically resolved with the administration of rHuEpo (recombinant human, Erythropoietin). However, as a result of an intense commercial campaign, strong therapies with this growth hormone, prescribed to achieve surprising sporting performances, got athletes to run the risk of thrombosis and vascular accidents because of red blood cells increase. Erythropoietin represents a significant subject of research. In fact, besides the ability of stimulating erythrocyte production, it has many pleiotropic effects. Several studies allow the assertion that EPO, in different concentr…
y
2007
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor
2004
The cytokine erythropoietin (Epo) is tissue-protective in preclinical models of ischemic, traumatic, toxic, and inflammatory injuries. We have recently characterized Epo derivatives that do not bind to the Epo receptor (EpoR) yet are tissue-protective. For example, carbamylated Epo (CEpo) does not stimulate erythropoiesis, yet it prevents tissue injury in a wide variety ofin vivoandin vitromodels. These observations suggest that another receptor is responsible for the tissue-protective actions of Epo. Notably, prior investigation suggests that EpoR physically interacts with the common β receptor (βcR), the signal-transducing subunit shared by the granulocyte-macrophage colony stimulating fa…